These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Biological and immunological properties of Sugi basic protein-pullulan conjugate. II. Is the reduced ability to elicit the Arthus reaction based on the poor activation of complement by immune complex consisting of anti-Sugi basic protein and Sugi basic protein-pullulan? Usui M; Taniguchi Y; Ando S; Kurimoto M; Matuhasi T Int Arch Allergy Appl Immunol; 1990; 91(1):74-9. PubMed ID: 2138137 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Strachan AJ; Shiels IA; Reid RC; Fairlie DP; Taylor SM Br J Pharmacol; 2001 Dec; 134(8):1778-86. PubMed ID: 11739255 [TBL] [Abstract][Full Text] [Related]
30. The inhibitory effect of rosmarinic acid on complement involves the C5 convertase. Peake PW; Pussell BA; Martyn P; Timmermans V; Charlesworth JA Int J Immunopharmacol; 1991; 13(7):853-7. PubMed ID: 1761351 [TBL] [Abstract][Full Text] [Related]
31. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. Strachan AJ; Woodruff TM; Haaima G; Fairlie DP; Taylor SM J Immunol; 2000 Jun; 164(12):6560-5. PubMed ID: 10843715 [TBL] [Abstract][Full Text] [Related]
32. The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes. Leslie RG; Nielsen CH Immunology; 2004 Jan; 111(1):86-90. PubMed ID: 14678202 [TBL] [Abstract][Full Text] [Related]
33. Evidence for different requirements in physical state for the interaction of lipopolysaccharides with the classical and alternative pathways of complement. Wilson ME; Morrison DC Eur J Biochem; 1982 Nov; 128(1):137-41. PubMed ID: 6756918 [TBL] [Abstract][Full Text] [Related]
35. Accumulation of platelets at sites of antigen-antibody-mediated injury: a possible role for IgE antibody and mast cells. Kravis TC; Henson PM J Immunol; 1977 May; 118(5):1569-73. PubMed ID: 140191 [TBL] [Abstract][Full Text] [Related]
36. Effects of immunological adjuvants on the mouse complement system. I. The inability of the polyanion heparin to act as an adjuvant is paralleled by inefficient alternative complement pathway inhibition. Klerx JP; Van Dijk H; Damen H; Rademaker PM; Willers JM Int J Immunopharmacol; 1983; 5(6):549-53. PubMed ID: 6662600 [TBL] [Abstract][Full Text] [Related]
37. Suppression of mouse complement activity by contaminants of technical grade pentachlorophenol. White KL; Anderson AC Agents Actions; 1985 Jul; 16(5):385-92. PubMed ID: 4050617 [TBL] [Abstract][Full Text] [Related]
38. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. Moran P; Beasley H; Gorrell A; Martin E; Gribling P; Fuchs H; Gillett N; Burton LE; Caras IW J Immunol; 1992 Sep; 149(5):1736-43. PubMed ID: 1380537 [TBL] [Abstract][Full Text] [Related]
39. Complement-inhibiting cucurbitacin glycosides from Picria fel-terrae. Huang Y; De Bruyne T; Apers S; Ma Y; Claeys M; Vanden Berghe D; Pieters L; Vlietinck A J Nat Prod; 1998 Jun; 61(6):757-61. PubMed ID: 9644059 [TBL] [Abstract][Full Text] [Related]
40. STUDIES ON THE LOCALIZATION OF CIRCULATING ANTIGEN-ANTIBODY COMPLEXES AND OTHER MACROMOLECULES IN VESSELS. I. STRUCTURAL STUDIES. COCHRANE CG J Exp Med; 1963 Oct; 118(4):489-502. PubMed ID: 14067901 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]